Clinical Trial Update: Secondary Prophylaxis After CMV Disease in Kidney Transplant Patients Targeted by γδ T Cells Immunomonitoring. [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating γδ T cell immunomonitoring for secondary prophylaxis of CMV disease in kidney transplant patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Transplant Infection

Snippet

Sponsor: University Hospital, Bordeaux | Conditions: Kidney Transplant Infection | Phase 2 | Status: COMPLETED